Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results

Syros Pharmaceuticals (NASDAQ:SYRSGet Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10, Zacks reports. Syros Pharmaceuticals had a negative return on equity of 227.91% and a negative net margin of 1,656.34%. During the same quarter last year, the company earned ($0.85) earnings per share.

Syros Pharmaceuticals Stock Up 0.9 %

Shares of SYRS stock traded up $0.05 during midday trading on Wednesday, reaching $5.48. 67,785 shares of the stock were exchanged, compared to its average volume of 199,360. Syros Pharmaceuticals has a 1 year low of $2.09 and a 1 year high of $8.17. The company’s 50 day moving average is $5.53 and its two-hundred day moving average is $5.54. The company has a current ratio of 3.95, a quick ratio of 3.95 and a debt-to-equity ratio of 2.07. The firm has a market cap of $146.48 million, a PE ratio of -0.94 and a beta of 1.75.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SYRS shares. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday. StockNews.com lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd.

Get Our Latest Research Report on SYRS

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Further Reading

Earnings History for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.